Signal // June 17, 2026
Everyone has the tools now. This week is about what that actually buys you.
Universal adoption, limited impact: pharma’s AI execution gap
A fresh TGaS Advisors brief finds that 100% of surveyed organisations now use generative AI, yet most still lack the governance, data foundations and operational discipline to move past pilots — its president calls the technology “table stakes.” For health communications, this is the quiet end of the adoption race: if everyone has the same tool, owning it differentiates no one. What separates teams now is the part the survey calls execution — judgement, governance and the ability to show value — which is exactly the part you can’t buy off the shelf.
Pharma arrives at Cannes ready to show its AI “receipts”
After several years of panels speculating about what AI might do, this year’s festival reportedly pushes brands and agencies to show what they actually built — including, more revealingly, where it didn’t work. One Pharma Lions juror notes that “humanity is unexpected” emerged as a standout theme across the case films. The signal for our field is that the credential is shifting from having an AI story to having an honest one; being able to say what failed is becoming the more persuasive position.
Is AI the fix for MLR, or the reason it breaks?
Promotional content volumes are climbing roughly 29% year on year while review capacity stays flat, and a large share of approved material is never used by field teams. Generative tools make producing more content trivial; they do nothing for the bottleneck, which was always review, not drafting. The uncomfortable implication is that AI can make the MLR problem worse before it makes it better — unless teams use it to send reviewers less and better, rather than simply more.
Amid the agentic-AI enthusiasm, the sober note worth keeping: by Gartner’s reckoning most vendor “agents” aren’t genuinely agentic, and it expects more than 40% of agentic AI projects to be scrapped by 2027 on cost, unclear value and weak risk controls. Before you buy anything badged “agentic,” the question to ask is plain — what decision does it actually make on its own, and what happens when it makes the wrong one. In a regulated field, an agent that can decide is also an agent that can decide wrongly, and the accountability stays with you.
That’s it for this edition. Back Friday.
— Ned